PedAM
Pediatric Disease Annotations & Medicines
| Disease | angioedema |
| Phenotype | C0019243|hereditary angioedema |
| Sentences | 7 |
| PubMedID- 20818887 | Conclusions: four hours after administration of ecallantide or placebo for acute attacks of angioedema in patients with hereditary angioedema, patient-reported treatment outcome scores and mean symptom complex severity scores were significantly better with ecallantide than with placebo. |
| PubMedID- 22171564 | Background: recombinant human c1-inhibitor (rhc1inh; ruconest(r)) has been developed for treatment of acute angioedema attacks in patients with hereditary angioedema (hae) due to heterozygous deficiency of c1inh. |
| PubMedID- 24565773 | Background: nanofiltered c1 inhibitor (human) is approved in the united states for routine prophylaxis of angioedema attacks in patients with hereditary angioedema, a rare disease caused by a deficiency of functional c1 inhibitor. |
| PubMedID- 20920772 | Recombinant human c1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. |
| PubMedID- 26171584 | Background: human plasma-derived nanofiltered c1 esterase inhibitor (c1 inh-nf) is used to treat acute angioedema attacks in patients with hereditary angioedema (hae), but data regarding use in children are sparse. |
| PubMedID- 22946752 | Conestat alfa is a recombinant human c1 inhibitor used in the treatment of angioedema attacks in patients with hereditary angioedema (hae). |
| PubMedID- 24278067 | Cost-utility analysis of ruconest((r)) (conestat alfa) compared to berinert((r)) p (human c1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema. |
Page: 1